Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer
In a small retrospective pilot study, the checkpoint inhibitor tislelizumab added to gemcitabine/cisplatin improved progression-free survival compared with gemcitabine/cisplatin alone among patients with locally advanced or metastatic bladder cancer.